Prolonged Disease Control with Nivolumab in Metastatic Lung Adenocarcinoma During Immunotherapy Era

Area of Science:

• Oncologic immunotherapy
• Thoracic oncology
• Cancer immunology

Background:

• Immune checkpoint inhibitors (ICIs) are crucial in cancer immunotherapy, particularly for refractory advanced lung cancer.
• Nivolumab targets the programmed cell death 1 (PD-1) and programmed cell death ligand-1 (PD-L1) pathway, enhancing anti-tumor immune responses.
• Nivolumab has demonstrated efficacy in thoracic malignancies, including non-small cell lung cancer (NSCLC).

Observation:

• A 52-year-old male with metastatic lung adenocarcinoma, progressing post-chemotherapy, received nivolumab treatment every two weeks.
• Initial treatment led to symptom relief (dyspnea) and biomarker regression (CEA, CRP).
• Radiological imaging indicated a stable disease response for approximately 1.5 years before progression.

Findings:

• Nivolumab therapy showed initial clinical and radiological benefit in a patient with metastatic lung adenocarcinoma.
• Biomarkers such as carcinoembryonic antigen (CEA) and C-reactive protein (CRP) initially regressed.
• The patient experienced a durable response for about 18 months before disease progression.

Implications:

• This case highlights the potential therapeutic value of nivolumab in managing advanced metastatic lung cancer.
• Immune checkpoint inhibition represents a significant advancement for patients with limited conventional treatment options.
• Further investigation into ICI efficacy in metastatic lung adenocarcinoma is warranted.